二极管激光经巩膜睫状体光凝术治疗急性闭角型青光眼持续性高眼压

目的 评价二极管激光经巩膜睫状体光凝术治疗急性闭角型青光眼持续性高眼压的疗效.方法 40例(40眼)原发性急性闭角型青光眼急性大发作患者,经72h应用多种降眼压药物治疗后眼压仍在40mmHg(1kPa=7.5 mmHg)以上,行二极管激光经巩膜睫状体光凝术.平均光凝能量(2290.00 ±149.01)mW,平均光凝点数(21.73±3.50)点.术后随访6～12个月,观察患者症状、眼压、视力变化和术后并发症等.结果 术后随访期间全部患者眼痛症状均缓解.术前平均眼压为(52.56±7.31)mmHg,末次随访时平均眼压(14.18±4.53)mmHg,术后眼压与术前相比,差异有显著统计学意义(P<0.001).术后平均视力(0.127 0±0.1650)较术前(0.033 4±0.0322)提高,差异也有显著统计学意义(P<0.01).光凝术后25眼(62.5%)视力提高,8眼(20.0%)视力无变化,7眼(17.5%)视力下降.术后前房炎症反应伴前房渗出3例,前房出血1例,药物治疗后消失.结论 二极管激光经巩膜睫状体光凝术治疗原发性急性闭角型青光眼持续性高眼压,疗效确切,可降低眼压,缓解疼痛,并发症少.     

半导体激光经巩膜睫状体光凝术治疗新生血管性青光眼的远期疗效

目的评价半导体激光经巩膜睫状体光凝术治疗新生血管性青光眼的远期疗效。方法回顾性分析71例（72眼）行半导体激光经巩膜睫状体光凝术的新生血管性青光眼,术前平均眼压为（56.2±12.0）mmHg（36～71mmHg,1kPa=7.5mmHg）,术后随访6个月～5a,观察眼部自觉症状、眼压、视力及并发症。结果最后1次随访的平均眼压为（17.3±5.9）mmHg（13～32mmHg）,降压成功率为94.4%.2眼发生眼球萎缩。视力提高7眼,视力无变化55眼,视力下降10眼。结论半导体激光经巩膜睫状体光凝术是一种简单、安全、有效的治疗新生血管性青光眼的方法。     

810nm激光睫状体光凝治疗难治性青光眼的疗效

目的:探讨810nm激光经巩膜睫状体光凝治疗难治性青光眼的临床疗效。方法:对25例30眼难治性青光眼患者行810nm激光经巩膜睫状体光凝术,术后随访3mo,分析术后眼压、疼痛感、视力、并发症等情况。结果:术后随访期间全部患者眼痛症状均缓解。术前平均眼压为50.42±2.50mmHg,末次随访时平均眼压15.95±4.19mmHg,术后眼压与术前相比,差异有显著统计学意义(P<0.01)。光凝术后2眼(6.7%)视力提高,24眼(80.0%)视力无变化,4眼(13.3%)视力下降。术后前房渗出12眼(40.0%),前房积血3眼(10.0%),玻璃体积血1眼(3.3%),药物治疗后消失。结论:810nm激光经巩膜睫状体光凝术是治疗难治性青光眼的有效方法,能显著降低眼压,减少患者痛苦,并发症少。     

难治性青光眼半导体激光经巩膜睫状体光凝术

目的　评价半导体激光经巩膜睫状体光凝术治疗难治性青光眼的效果和安全性。方法　 68例 (69眼 )接受治疗 ,术后随访 6～ 17月。分析末次治疗后第 6月的眼压、视力和眼部症状。结果　无光感组 (3 6眼 ) :光凝术前眼压 (61.16± 12 .44 )mmHg(1mmHg =0 .13 3kPa) ,末次光凝术后第 6月后 3 3眼眼压 (2 9.67± 6.79)mmHg。 3眼眼球萎缩 ,12眼需 2次或多次治疗。光感及光感以上组 (3 3眼 ) :光凝术前眼压 (5 1.72± 13 .85 )mmHg ,末次光凝术后第 6月眼压 (2 1.42± 8.2 2 )mmHg。其中 11眼需要 2次或 3次光凝术 ,4眼 3次光凝术后眼压仍高于 2 1mmHg。结论　半导体激光经巩膜睫状体光凝术是一种简单、安全、有效的治疗难治性青光眼的方法 ,但常需要重复治疗。     

经巩膜睫状体光凝治疗难治性青光眼的临床观察

目的:评价半导体激光经巩膜睫状体光凝术治疗难治性青光眼的效果。方法:回顾性分析55例56眼难治性青光眼的临床资料,均行睫状体光凝,术后随访观察并记录眼压、视力、眼部自觉症状以及并发症,随访时间3mo以上。结果:术前平均眼压53.5±18.7mmHg,末次随访平均眼压为19.4±9.6mmHg,术后眼压与术前眼压相比,差别具有统计学意义(P<0.01)。术后44眼视力无变化,2眼视力提高,10眼视力下降;眼痛均消失或缓解;并发症少,主要有葡萄膜炎、前房出血等。结论:睫状体光凝能有效降低难治性青光眼患者的眼压,且并发症少。     

睫状体光凝术治疗玻璃体切割术后继发青光眼的疗效

目的：评估睫状体光凝术治疗玻璃体切割术后(水眼)继发青光眼的安全性和有效性。

方法：回顾性分析我院2014-10/2016-10收治的玻璃体切割术后(水眼)继发青光眼患者20例20眼的临床资料,对所有患者进行经巩膜睫状体光凝术,术后持续随访3mo,观察术后视力、眼压和并发症情况。

结果：术后1mo时,9眼眼压控制不佳,4眼再次行睫状体光凝术后3眼眼压降至正常。末次随访时,视力较术前差异无统计学意义(P=0.655); 14眼(70%)患者眼压得到有效控制,眼压(24.6±11.4mmHg)较术前(42.3±5.9mmHg)改善,差异有统计学意义(P<0.05)。术后未出现眼球萎缩、脉络膜上腔出血等严重并发症。

结论：睫状体光凝术对玻璃体切割术后(水眼)继发青光眼患者是一种安全有效、可重复的手术方式。     

经巩膜睫状体光凝治疗难治性青光眼

目的　评价难治性青光眼行二极管激光巩膜睫状体光凝 (transcleraldiodelasercyclophotocoagulation ,TDLCP)的有效性和安全性。方法　观察 6 6例 6 6眼行TDLCP治疗前后用抗青光眼药物的种类、患者的自觉症状、治疗前后眼压、视力及术后并发症 ,随访 1a。结果　抗青光眼药物种类手术前后分别平均为 2 .6种 (1～ 4种 )和 1.8种 (0～ 3种 ) ,治疗后比治疗前用药明显减少 (P <0 .0 0 1)。术后 5 5例疼痛消失 ,9例疼痛明显减轻 ,2例仍有明显疼痛。治疗前后平均眼压分别为 (35 .2± 7.9)mmHg(18～ 80mmHg) (1kPa =7.5mmHg)及(19.5± 6 .2 )mmHg(4～ 6 8mmHg) ,眼压平均下降 15 .4mmHg ,治疗前后有统计学意义 (P <0 .0 0 1)。术后视力提高10眼 ,视力无变化 4 0眼 ,视力下降 16眼。术后并发症为早期前房炎症反应 4 2眼 ,前房出血 5眼 ,角膜水肿 2 3眼 ,术眼光感丧失 5眼 ,眼球萎缩 3眼。结论　虽然经巩膜睫状体光凝术后会发生前房出血、低眼压、眼球萎缩等并发症 ,但其能显著降低眼压、减少患者痛苦并可减少抗青光眼用药 ,因此仍为目前治疗难治性青光眼的一种有效治疗方法     

二极管激光经巩膜睫状体光凝术治疗难治性青光眼

目的 观察二极管激光经巩膜睫状体光凝术治疗难治性青光眼的临床疗效.方法 回顾性分析北京同仁医院2007年9月至2008年8月107例(110眼)难治性晚期青光眼患者临床资料,均行二极管睫状体光凝,分析术后眼压、疼痛感、视力、并发症等情况.结果 术后第1天平均眼压(15.90±12.30)mmHg(1 kPa=7.5 mmHg),术后1周平均眼压(14.70±5.21)mmHg,术后1个月平均眼压(14.02±9.50)mmHg,术后3个月平均眼压(14.51±11.30)mmHg,术前与术后第1天、1周、1个月及3个月眼压差异均有统计学意义(均为P<0.01).术后89眼(80.9%)视力不变,17眼(15.5%)视力下降,4眼(3.6%)视力提高.83.6%的患者眼痛症状明显缓解或消失.术后发生前房渗出12眼(10.9%),前房积血6眼(5.4%),玻璃体积血2眼(1.8%),巩膜溶解2眼(1.8%),巩膜穿孔1眼(0.9%).结论 二极管激光经巩膜睫状体光凝术是治疗难治性晚期青光眼的有效方法,能显著降低眼压,减少患者痛苦,并发症少,可重复治疗.     

二极管激光经巩膜睫状体光凝术治疗难治性青光眼

目的:研究二极管激光经巩膜睫状体光凝术治疗难治性青光眼的有效性及激光治疗参数。方法:对我院收治的50例50眼晚期难治性青光眼患者行二极管激光经巩膜睫状体光凝术,记录每位患者所用能量,击射范围,光凝点数,爆破点数,观察患者治疗前后的眼压、眼部症状,视力、裂隙灯观察眼前节的改变和并发症等。结果:术后平均眼压(18.50±2.50)mmHg,术后眼压较术前明显下降(P<0.01)。术后46眼疼痛明显减轻,术前术后眼压差值与击射能量的相关性不高;眼压下降值与击射范围、击射点数呈正相关性,眼压下降值与爆破点数显著相关,呈正相关性。结论:二极管激光经巩膜睫状体光凝术治疗难治性青光眼是一种安全有效的方法,激光治疗参数需根据术前眼压、不同类型青光眼进行设计。     

睫状体光凝联合前房穿刺术对新生血管性青光眼的止痛效果观察

目的分析新生血管性青光眼半导体激光经巩膜睫状体光凝术后眼痛症状的成因及联合前房穿刺术后对减轻眼痛症状的效果。方法 35例（35眼）青光眼以半导体激光经巩膜的睫状体光凝联合前房穿刺术。术后随访眼压及疼痛6个月以上。结果术前平均眼压（56.73±21.62）mmHg,术后第2周平均眼压（28.36±11.01）mmHg（t=8.099,P=0.001）。术前轻度疼痛5眼,重度疼痛22眼,剧痛8眼;术后第2周无痛22眼,轻度疼痛11眼,重度疼痛2眼;术后1月只有1眼仍有轻度疼痛,2月后疼痛消失。结论新生血管性青光眼半导体激光经巩膜睫状体光凝联合前房穿刺术可以有效地减轻术后疼痛。     

眼外伤玻璃体术后青光眼应用睫状体光凝联合前房穿刺治疗观察

目的 探讨经巩膜睫状体光凝联合前房穿刺术治疗眼外伤玻璃体切除术后难治性青光眼的效果.方法 回顾复杂性眼外伤玻璃体手术后难治性青光眼41例(41只眼),采用经巩膜睫状体光凝联合前房穿刺术治疗,术后随访3-12个月.结果 41只眼中,手术前眼压是(43.14±12.37)mmHg,术后最后一次随访眼压为(19.76±7.06)mmHg,手术后眼压明显下降,(t=6.5742,P＜0.001).5只眼视力略有提高,33只眼无变化,3只眼视力下降.术后1只眼眼球萎缩.结论 经巩膜睫状体光凝联合前房穿刺术是治疗眼外伤玻璃体手术后难治性青光眼一种安全有效的方法.

Abstract：

Objective To evaluate the clinical effects of transscleral diode laser cyclophotocoagulation and paracentesis of anterior chamber for traumatic refractory glaucoma following vitrectomy.Methods Forty-one cases (41 eyes) with traumatic refractory glaucoma following vitrectomy were received the transscleral diode laser cyclophotocoagulation and paracentesis of antenor chamber, the patients were followed three to twelve months. Results The intraocular pressure (IOP) were (43.14±12.37) mmHg before treatment. IOP were (19.76±7.06) mmHg in the last following-up. IOP was significantly decreased by this surgery (P <0.001). The visual acuity in following-up, 5 eyes was unproved, 33 stable and 3 eyes decreased. One eye was atrophiabulbi. Conclusions Transscleral diode laser cyclophotocoagulation and paracentesis of anterior chamber is a safe and effective treatment for traumatic refractory glaucoma following vitrectomy.     

Diode laser in secondary glaucoma in children--long-term results

This paper presents effectiveness and safety of transscleral contact cyclophotocoagulation with diode laser (TSCPC) in secondary glaucoma in children. Fifteen eyes of 15 children at the age from 4 to 18 years were examined. Majority of patients was aphakic after congenital and traumatic cataract extraction. Microphtalmus, nystagmus and dysgenesis mesodermalis was observed. Eleven eyes had undergone at least one previous trabeculectomy, 9 eyes -cyclokrioaplication and 4 eyes perforate diathermy. In all patients diode laser transscleral cyclophotocoagulation has been performed. The number of procedures per one eye, intraocular pressure (IOP), visual acuity and complications after TSCPC was estimated. Follow-up ranged from 3 to 5 years, mean 4.13 years. TSCPC was performed once in 3 eyes, twice in 6 eyes, three times in 4 eyes and four times in 2 eyes, mean 2.33 procedures per eye. Before the treatment mean IOP was 34.0 mmHg. Decreasing of IOP was observed in 73.3% of eyes. The final mean postoperative IOP was 20.07 mmHg. Visual acuity before operation ranged from no light perception to 0.0001, mean 0.0081. After TSCPC no light perception was noted in 2 eyes. Visual acuity recovered in 1 eye. Mean Length of the eye globe before treatment was 24.48 mm. No changes of length after cyclophotocoagulation were noted. CONCLUSIONS: cyclophotocoagulation by diode laser is a useful therapy for the treatment of secondary pediatric glaucomas with uncontrolled IOP in the long term.     

二极管激光经巩膜睫状体光凝治疗新生血管性青光眼

目的:评价二极管激光经巩膜睫状体光凝治疗新生血管性青光眼的疗效。方法:对52例诊断为新生血管性青光眼的患者行经巩膜的810nm激光睫状体光凝,能量为1500~3000mW,时间2000ms,范围为24~32点,随访1a,观察其治疗效果。结果:治疗前眼压为(57.78±6.46)mmHg,治疗3d后眼压为(30.8±5.41)mmHg,与治疗前相比,差异显著;随访1a后眼压为(19.44±4.38)mmHg,与治疗前相比,差异显著。所有患者的疼痛均得到缓解或消除。结论:经巩膜睫状体光凝治疗新生血管性青光眼是有效和安全的。     

Supplemental transscleral diode laser cyclophotocoagulation after aqueous shunt placement in refractory glaucoma

OBJECTIVE: To assess the outcome of supplemental transscleral diode laser cyclophotocoagulation after aqueous tube shunt placement to obtain effective intraocular pressure (IOP) control. DESIGN: Retrospective non-comparative case series. PARTICIPANTS: Twenty-one eyes in 21 subjects with uncontrolled IOP despite the presence of an aqueous tube shunt and maximally tolerated glaucoma medications. INTERVENTION: Supplemental transscleral diode laser cyclophotocoagulation was performed. MAIN OUTCOME MEASURES: Reduction of intraocular pressure and reduction of glaucoma medications. RESULTS: Twelve adults and nine children underwent supplemental transscleral diode cyclophotocoagulation and were followed postoperatively for a mean of 26.9 +/- 13.4 (standard deviation [SD]) months (range, 7-58 months). Average IOP was significantly reduced from a preoperative level of 35.7 +/- 14.7 (SD) mmHg to a postoperative level of 13.6 +/- 7.1 (SD) mmHg (P < 0.001) with the mean number of medications significantly reduced to 1.5 +/- 1.3 (SD) (P < 0.001). Seven subjects (33%) had additional laser treatment to achieve IOP control. Six subjects who were therapy failures included three who developed no light perception in the setting of proliferative diabetic retinopathy, one subject with chronic angle-closure glaucoma who gradually developed no light perception after refusing further treatment or medication, and two subjects who developed retinal detachments. One child who was a qualified success underwent enucleation and debulking of an enlarging neurofibroma that caused significant proptosis and disfigurement. CONCLUSIONS: In cases of glaucoma that are uncontrolled despite a glaucoma aqueous tube shunt and multiple medications, adjunctive transscleral diode cyclophotocoagulation treatment(s) is a viable option to lower IOP.     

透巩膜睫状体光凝治疗难治性青光眼的疗效观察

目的 评价半导体激光透巩膜睫状体光凝治疗难治性青光眼的临床疗效.方法 取38只眼难治性青光眼,眼压30.9-66.23mmH,平均(45.1±12.98)mmHg,应用激光能量1500～2500mW,脉冲2s,治疗范围270°-300°,观察术后1d、1周、1和3月时患眼的眼压,疼痛情况和并发症.结果 (1)术后1d眼压9.3-33.1mmHg,平均(24.47±8.51)mmHg,术后1周眼压7.5-32.5mmHg,平均(21.67±7.92)mmHg,术后1月眼压5.8～35.5mmHg,平均为(21.02±10.7)mmHg,术后3月眼压4.2-35.8 mmHg,平均(20.03±9.82)mmHg.术后各时间点眼压与术前眼压配对t检验,t值分别为7.11、10.09、8.82和10.03,均P＜0.0001,差异有统计学意义;(2)术后34只眼(89.47%)疼痛明显缓解;(3)并发症有球结膜灼伤水肿2只眼,前房积血23只眼,葡萄膜炎反应18只眼,角膜上皮脱落2只眼.结论 透巩膜睫状体光凝创伤小,早期治疗效果明显,操作简便,能有效降低眼压,缓解难治性青光眼的疼痛.     

经巩膜睫状体光凝术治疗难治性青光眼的效果

目的:评价经巩膜睫状体光凝术(TCP)治疗难治性青光眼的效果。方法:回顾性研究。对北京爱尔英智眼科医院2017年7月至2018年12月行TCP治疗的难治性青光眼73例(81只眼)的临床资料进行分析。观察手术前后眼压、降眼压药物使用种类、术中光凝情况和并发症的发生。术后随访6个月。结果:术前眼压(35.0±8.8)mmH...     

改良二极管激光睫状体光凝术治疗中晚期青光眼

目的探讨经巩膜二极管激光睫状体光凝术(transscleral cyclophotocoagulation,TDLC)激光斑点数的选择治疗中晚期青光眼患者的疗效。方法连续收集2009年7月至2010年3月在我院接受TDLC治疗的不同类型中晚期青光眼患者27例27眼。根据青光眼患者术前眼压由低到高分为3组:在激光功率和持续时间(1500ms)不变的情况下,给予不同激光斑点数。随访术后1d、7d、14d、30d、60d、90d和180d的眼压,观察术后的近、中期效果。结果 27例27眼患者术前眼压为27～72(53.15±10.85)mmHg(1kPa=7.5mmHg),术后1d眼压为(28.78±7.40)mmHg,术后180d眼压为(18.37±2.02)mmHg。术后各阶段眼压平稳下降,并最终达到或接近正常眼压。术后任何同一时间点,90点组的术前术后眼压差都比70点组高,27例患者术后均未见视力下降发生。结论在激光功率和持续时间不变的情况下,按术前眼压给予不同的激光斑点数能更有效地控制术后眼压,不会增加并发症的发生和降低术后视力。     

Contact transscleral diode cyclophotocoagulation for refractory glaucoma

PURPOSE: To evaluate the effect of contact transscleral diode cyclophotocoagulation on intraocular pressure (IOP), vision, number of medications, and complications in a heterogenous population of patients with refractory glaucoma. METHODS: Clinical data for all patients undergoing contact transscleral diode cyclophotocoagulation for refractory glaucoma at the Medical College of Georgia between November 1994 and November 1996 were reviewed. Forty-seven eyes of forty-seven patients followed for at least one month were included. Visual acuity, IOP, number of medications, and complications were noted for follow-up periods as long as 24 months. RESULTS: At final follow-up examination (range 1-24 months, median 9 months), the average decrease in IOP was 21+/-16 mmHg. Thirty-one (66%) patients had final IOP between 7 and 21 mmHg. Medications were decreased by an average of 1.1. Twenty-six (62%) of 42 patients with vision before surgery had stable or improved visual acuity at the final follow-up visit; 16 (38%) had a deterioration in visual acuity. Neovascular glaucoma was associated with a posttreatment IOP less than 7 mmHg. CONCLUSION: Contact transscleral diode cyclophotocoagulation is effective in lowering IOP in eyes with refractory glaucoma. It also serves to reduce the number of medications required for appropriate IOP control. Loss of visual acuity remains an important concern. Acute complications tend to be transient. Further study is needed to identify patients at risk for markedly reduced IOP after this procedure and for modulation of the protocol to decrease such risk.     

Visual loss after transscleral diode laser cyclophotocoagulation for primary open-angle and neovascular glaucoma.

BACKGROUND AND OBJECTIVE: Varying incidences of visual loss after transscleral diode laser cyclophotocoagulation for uncontrolled intraocular pressure (IOP) have been reported. This study compared the treatment response in primary open-angle (POAG) and neovascular (NVG) glaucoma, particularly regarding vision loss. PATIENTS AND METHODS: Case notes of consecutive patients who underwent transscleral diode laser cyclophotocoagulation between March 2001 and September 2005 were retrospectively reviewed. A diagnosis of POAG or NVG and at least 6 months of follow-up were required for inclusion. Conservative laser parameters were used. The treatment response of the POAG and NVG groups was compared. RESULTS: Twenty-five eyes of23 patients with POAG and 14 eyes of 14 patients with NVG were studied. Mean follow-up was 22.4 and 12.9 months in the POAG and NVG groups, respectively. Post-treatment, both groups had significant reduction in mean IOP of 7.3 (29.2%) and 13.2 (36.6%) mm Hg, respectively (between group P = .18). One eye in each group had mild hypotony of 4 mm Hg, and no eyes became phthisical. Oral acetazolamide treatment was significantly reduced in both groups. Visual acuity post-treatment decreased in both groups; the POAG eyes had better initial visual acuity and lost more visual acuity. Nine of 25 (36%) POAG and 4 of 8 (50%) NVG eyes lost 2 or more LogMAR lines. CONCLUSIONS: Transscleral diode laser cyclophotocoagulation reduced IOP and medication requirements in POAG and NVG. Patients should be warned that visual loss may occur, especially in endstage glaucoma.